Clinical Trial: Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants

U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07333144) titled 'Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants' on Dec. 30, 2025.

Brief Summary: Gastrointestinal bleeding (GIB) is a common emergency in hepatology and gastroenterology, with an overall mortality rate ranging from 5% to 10% depending on the study. GIB is classified into two categories: upper GIB (80% of cases) and lower GIB (20% of cases). There are many risk factors for GIB, including anticoagulants. In cases of GD under anticoagulants, there are specific management recommendations. In particular, in cases of severe bleeding under direct oral anticoagulants (DOACs), it is recommended to stop treatment and...